Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 4/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12617369 | 1.00 | CACNA2D1 (0.40) | CACNA2D1CACNA1BCACNB1CACNA1CREN | |
| SCHEMBL31467987 | 0.85 | NCF1 (0.38) | CACNA2D1CACNA1BCACNB1CACNA1CHTR1A | |
| SCHEMBL5967438 | 0.83 | — | — | |
| SCHEMBL1295911 | 0.83 | CPN1 (0.41) | RENACEALDH1A1CPN1CPB2 | |
| SCHEMBL11310195 | 0.81 | CPN1 (0.44) | RENACEMAPTCPN1CPB2 | |
| SCHEMBL6559712 | 0.78 | ALDH1A1 (0.37) | CACNA2D1CACNA1CRENACEALDH1A1 | |
| SCHEMBL1208925 | 0.78 | ALDH1A1 (0.55) | RENACEALDH1A1 | |
| SCHEMBL8651989 | 0.78 | ALDH1A1 (0.55) | RENACEALDH1A1 | |
| SCHEMBL6808670 | 0.78 | ALDH1A1 (0.55) | RENACEALDH1A1 | |
| SCHEMBL8967209 | 0.75 | NCF1 (0.38) | CACNA2D1CACNA1BCACNB1CACNA1CHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110195994-A1 | Piperidinyl GPCR Agonists | PROSIDION LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100048625-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048632-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100048631-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022591-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | CACNA2D1 1900/4885CACNA1B 976/4885CACNB1 1719/4885 |
| US-20110195994-A1 | Piperidinyl GPCR Agonists | GPR119, GPR27, GLP1R | CACNA2D1 2431/4885CACNA1B 1174/4885CACNB1 1886/4885 |
| US-20100048632-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | CACNA2D1 1900/4885CACNA1B 976/4885CACNB1 1719/4885 |
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | CACNA2D1 2431/4885CACNA1B 1174/4885CACNB1 1886/4885 |
| US-20100286112-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, DPP4, DPP9 | CACNA2D1 2882/4885CACNA1B 2038/4885CACNB1 2872/4885 |
| US-20100105732-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | CACNA2D1 1900/4885CACNA1B 976/4885CACNB1 1719/4885 |
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | CACNA2D1 1830/4885CACNA1B 983/4885CACNB1 1670/4885 |
| US-20100048631-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | CACNA2D1 1900/4885CACNA1B 976/4885CACNB1 1719/4885 |
| US-20100048625-A1 | PIPERIDINE GPCR AGONISTS | GPR119, GPR27, GLP1R | CACNA2D1 1900/4885CACNA1B 976/4885CACNB1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.